


88
59

oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E157)	tetrahydro-1H-3-benzazepine (E148)	
3-Cyclobutyl-7-([(3S)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-3-piperidinyl)methyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E158)	3-Cyclobutyl-7-([(3S)-3-piperidinylmethyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E149)	427
3-Cyclobutyl-7-([(3S)-1-(tetrahydro-2H-pyran-4-ylcarbonyl)-3-piperidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E159)	3-Cyclobutyl-7-([(3S)-3-piperidinyl]oxy)-2,3,4,5-tetrahydro-1H-3-benzazepine (E150)	413

Example 160

6-[4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinecarbonitrile (E160)



5 3-Cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E6) (80 mg, 0.2 mmol), 6-chloronicotinonitrile (31 mg, 0.22 mmol) and triethylamine (0.03 ml, 0.22 mmol) were dissolved in acetonitrile (2 ml) and heated to 180 °C in a microwave reactor for 10 minutes. The reaction mixture was diluted with ethyl acetate and washed with water, brine and dried (magnesium sulfate). The organic layer was filtered, concentrated *in vacuo* and the resulting residue purified by column chromatography eluting with a mixture of 10 ammonia: ethanol: dichloromethane (0.25: 2.25:97.5 to 1:9:90) to afford the title compound (E160); MS (ES+) *m/e* 403 [M+H]⁺.


15 Examples 161-166

Examples 161-166 (E161-E166) were prepared from 3-cyclobutyl-7-(piperidin-4-yloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine (E6) and the appropriate chloride indicated in the table using an analogous method to that described for Example 160 (E160):


Example	Chloride	LC/MS (M+H ⁺)
6-[4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-(cyclopropylmethyl)-3-pyridinecarboxamide (E161)	6-Chloro-N-(cyclopropylmethyl)-3-pyridinecarboxamide (D36)	475
7-[(1-[5-(1-Azetidinylcarbonyl)-2-pyridinyl]-4-piperidinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepine (E162)	5-(1-Azetidinylcarbonyl)-2-chloropyridine (D37)	461
3-Cyclobutyl-7-[(1-[5-(4-morpholinylcarbonyl)-2-pyridinyl]-4-piperidinyl)oxy]-2,3,4,5-	1-(6-Chloro-pyridin-3-yl)-1-morpholin-4-yl-methanone	491

59
60

tetrahydro-1H-3-benzazepine (E163)	(D5)	
6-{4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl}-N-methyl-3-pyridinecarboxamide (E164)	6-Chloro-N-methyl-nicotinamide (D10)	435
2-{4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl}-4-pyridinecarbonitrile (E165)	2-Chloro-4-pyridine carbonitrile	403
3-Cyclobutyl-7-[[1-(2-pyrazinyl)-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E166)	2-Chloropyrazine	379

Example 167a**Ethyl 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]butanoate (E167a)**

- 5 Ethyl 4-bromobutyrate (2 ml, 13.8 mmol) was added to a stirred solution of 3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol (E3) (2.00 g, 9.2 mmol) and potassium carbonate (3.8 g, 27.6 mmol) in 2-butanone (50 ml). After stirring at reflux for 24 hours, the reaction mixture was cooled to room temperature, filtered and concentrated *in vacuo*. The resulting crude material was purified by column chromatography eluting with a mixture of methanol: dichloromethane (5: 95) to afford the title compound (E167a). MS (ES+) *m/e* 332 [M+H]⁺
- 10

Example 167b**4-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]butanoic acid (E167b)**

- 15 Ethyl 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]butanoate (E167a) (1.5 g, 4.5 mmol) was diluted in ethanol (30 ml) and treated with 2N sodium hydroxide (7.9 ml). After stirring at reflux for 24 hours, the reaction mixture was cooled to room temperature, filtered and concentrated *in vacuo*. The crude mixture was applied to a SCX ion exchange cartridge (Varian bond-elute) and washed with water, methanol and then a mixture of .880 ammonia:methanol (1:9). The combined basic fractions were reduced *in vacuo* to afford the title compound (E167b) as the ammonium salt. MS (ES+) *m/e* 303 [M+H]⁺
- 20

Example 167

- 25 **3-Cyclobutyl-7-[[4-oxo-4-(1-piperidinyl)butyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine (E167)**

